Tazemetostat showed promise in a number of preclinical models of various tumour types.205,206 14-day, 1 μM treatment of SMARCB1-deleted malignant rhabdoid tumour (an aggressive childhood cancer)207 cells led to a reduction in H3K27me3 marks with concurrent growth inhibition. This evidence concerns the gene SMARCB1 and neoplasm.